Company: IMNN
Filing Date: 2025-06-09
Form Type: DEF 14A
Source: 0001641172-25-014324
Chunk: 22

Company: Imunon, Inc.
Filing Date: 2025-06-09
Form: DEF 14A
Chunk 22
---
100, Lawrenceville, NJ 08648. In the event of any amendments to or waivers of the terms of the Code of Ethics, such matters will be posted promptly to the Company’s website in lieu of disclosure on Form 8-K in accordance with Item 5.05(c) of Form 8-K.

Committees of the Board of Directors

Our Board of Directors implements its risk oversight function both as a whole and through delegation to various committees (the “Board Committees”). These Board Committees meet regularly and report back to our full Board of Directors.

| ● | Our                                                                                                                                       
 Audit Committee oversees the management of financial, accounting, internal controls, disclosure controls and the engagement arrangement   
 and regular oversight of the independent auditors.                                                                                        |
| ● | Our                                                                                                                                       
 Compensation Committee is responsible for the design and oversight of our compensation programs. Based on a review of our company-wide    
 compensation programs, including the compensation programs for our executive officers, our Compensation Committee has concluded that      
 these programs do not create risks that are likely to have a material adverse effect on us.                                               |
| ● | Our Nominating and Governance Committee periodically reviews our corporate governance practices, including the risks that those practices 
 are intended to address. It                                                                                                               
 also periodically reviews the composition of our Board of Directors to help ensure that a diversity of skills and experiences is          
 represented by the members of our Board of Directors, taking into account the stage of our growth and strategic direction.                |
| ● | Our                                                                                                                                       
 Science and Technology Committee assists our Board of Directors in monitoring the state of science and technology capabilities within     
 the Company and associated risks and overseeing the development of key technologies and major science and medicine-driven innovation      
 initiatives essential to our long-term success.                                                                                           |

Audit Committee

Our Audit Committee consists of Mr. James A. Dentzer (Chair), Mr. Frederick J. Fritz and Ms. Christine Pellizzari. Our Audit Committee operates under a written charter that is available on our web site, located at http://www.imunon.com. Additional copies of the charter are available upon written request to us.

Our Audit Committee assists our Board of Directors in fulfilling its responsibility to oversee management’s implementation of our financial reporting process. In discharging its oversight role, the Audit Committee reviewed and discussed the audited financial statements contained in our 2024 Annual Report on Form 10-K with our management and independent registered public accounting firm. Management is responsible for the financial statements and the reporting process, including the system of internal controls. Our independent